Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000002.xml
Aktuelle Dermatologie 2022; 48(05): 209-217
DOI: 10.1055/a-1773-9174
DOI: 10.1055/a-1773-9174
Übersicht
Immunologie Update für Dermatologen – woran wird geforscht?
Immunology: Update for Dermatologist – what is being researched?
Zusammenfassung
Immuntherapien haben die Behandlung der chronischen Dermatosen enorm vorangebracht. Immunologische Diagnostik bestimmt den Alltag in der Praxis. Viele Dermatologen impfen. Nicht zuletzt die allgegenwärtige Corona-Pandemie und die Entwicklung entsprechender Impfstoffe verdeutlichen das große Forschungspotenzial in der Immunologie. Wir versuchen, einen Überblick zu geben, woran aktuell immunologisch geforscht wird und was wir in naher Zukunft zu erwarten haben.
Abstract
Immunotherapies have been contributing significantly to the successful treatment of chronic dermatoses. Immunological diagnosis and therapy are being increasingly used in our dermatological practice. Additionally, many dermatologists also administer vaccines now. The omnipresent corona pandemic and the resulting development of vaccines have clearly demonstrated the enormous research potential in immunology and dermatology; the latter resulting in the new additional qualification of immunology for dermatologists. We offer an overview of our current immunological research projects and what we expect to have to deal with in our practice in the near future.
Publication History
Article published online:
19 May 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Diamanti E, Föhr J, Papageorgiou A. et al. Immunologie in der dermatologischen Praxis – wieviel, warum, wann?. Akt Dermatol 2022; 48: 201-208 DOI: 10.1055/a-1699-5440.
- 2 Altan-Bonnet G, Mukherje R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. Nature Rev Immunol 2015; 19: 205-217
- 3 Brown C, Mackall CL. CAR T cells therapy: inroads to response and resistance. Nature Rev Immunol 2019; 19: 73-74
- 4 Sonnenberg GF, Artis D. Novel connections and precision approaches. Nature Rev Immunol 2019; 19: 75-76 DOI: 10.1038/s41577-018-0114-3. (PMID: 30622346)
- 5 Burton DR. Advancing an HIV vaccine; advancing vaccinology. Nature Rev Immunol 2019; 19: 77-78 DOI: 10.1016/j.vaccine.2020.12.085. (PMID: 33487466)
- 6 Heneka MT. Microglia take centre stage in neurodegenerative disease. Nature Rev Immunol 2019; 19: 79-80 DOI: 10.1038/s41577-018-0112-5. (PMID: 30610221)
- 7 Kanneganti T-D. The signposts and winding roads to immunity and inflammation. Nature Rev Immunol 2019; 19: 81-82 DOI: 10.1038/s41577-018-0108-1. (PMID: 30602731)
- 8 Mathis D. Organismal immunometabolism: advances in both directions. Nature Rev Immunol 2019; 19: 83-84
- 9 Russel DG, Huang L, VanderVen BC. Immunometabolism at the interface between macrophages and pathogens. Nature Rev Immunl 2019; 19: 291-304
- 10 OʼSullivan D, Sanin DE, Pearce EJ. et al. Metabolic interventions in the immunes response to cancer. Nature Rev Immunol 2019; 19: 324-335
- 11 Tarlinton D. B cells still front and centre immunology. Nature Rev Immunol 2019; 19: 85-86 DOI: 10.1038/s41577-018-0107-2. (PMID: 30602730)
- 12 Brodin P. Systems-level patterns emerge. Nature Rev Immunol 2019; 19: 87-88 DOI: 10.1038/s41577-018-0106-3. (PMID: 30604773)
- 13 Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nature Rev Immunl 2021; 21: 245-256
- 14 Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nature Rev Immunol 2019; 19: 599-613
- 15 Zhang Q, Xuetao C. Epigenetic regulation of the innate immune response to infection. Nature Rev Immunol 2019; 19: 417-432
- 16 Johanson TM, Chan WF, Keenan CR. et al. Genome organization in immune cells: unique challenges. Nature Rev Immunol 2019; 19: 448-456
- 17 Skelly AN, Sato Y, Kearny S. et al. Mining the microbiota for microbial and metabolite-based immunotherapies. Nature Rev Immunol 2019; 19: 305-323
- 18 Renz H, Skevaki C. Early life microbial exposures and allergy risks: opportunities for prevention. Nature Rev Immunol 2021; 21: 177-191 DOI: 10.1038/s41577-020-00420-y. (PMID: 32918062)
- 19 Raffin C, Vo LT, Bluestone JA. Treg cell-based therapies: challenges and perspectives. Nature Rev Immunol 2020; 20: 158-172 DOI: 10.1038/s41577-019-0232-6. (PMID: 31811270)
- 20 Angkasekwinai P, Dong C. IL-9-producing T cells : potential players in allergy and cancer. Nature Rev Immunol 2021; 21: 37-48 DOI: 10.1038/s41577-020-0396-0. (PMID: 32788707)
- 21 McInnes IB, Gravallese EM. Immune-mediated inflammatory disease therapeutics: past, present and future. Nature Rev Immunol 2021; 21: 680-686 DOI: 10.1038/s41577-021-00603-1. (PMID: 34518662)
- 22 St John AL, Rathore APS. Adaptive immune responses to primary and secondary dengue virus infections. Nature Rev Immunol 2019; 19: 218-230
- 23 Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. Nature Rev Immunol 2019; 19: 457-471 DOI: 10.1038/s41577-019-0158-z. (PMID: 30940932)
- 24 Julien J-P, Wardemann H. Antibodies against Plasmodium faclciparum at the molecular level. Nature Rev Immunol 2019; 19: 761-775
- 25 Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. Nature Rev Immunol 2022; 22: 7-18 DOI: 10.1038/s41577-021-00657-1. (PMID: 34873279)
- 26 Lynn DJ, Saoirse CB, Lynn MA. et al. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nature Rev Immunol 2022; 22: 33-46
- 27 Haynes BF. SARS-CoV-2 and HIV-1 – a tale of two vaccines. Nature Rev Immunol 2021; 21: 543-544 DOI: 10.1038/s41577-021-00671-3. (PMID: 34903878)
- 28 Wong L-YR, Perlman S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses – are we our own worst enemy?. Nature Rev Immunol 2022; 22: 47-56
- 29 Boyton RJ, Altman DM. The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?. Nature Rev Immunol 2021; 21: 762-768
- 30 Jeyanathan M, Afkhami S, Smaill F. et al. Immunological considerations for COVID-19 vaccine strategies. Nature Rev Immunol 2020; 20: 615-632 DOI: 10.1038/s41577-020-00434-6. (PMID: 32887954)
- 31 Lipsitch M, Krammer F, Regev-Yochay G. et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nature Rev Immunol 2022; 22: 57-65 DOI: 10.1038/s41577-021-00662-4. (PMID: 34876702)
- 32 Ho AW, Kupper TS. T cells and the skin: from protective immunity to inflammatory skin disorders. Nature Rev Immunol 2019; 19: 490-502
- 33 Cromer D, Juno JA, Khoury D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of infection. Nature Rev Immunol 2021; 21: 395-404
- 34 Blank CU, Haining WN, Held W. et al. Defining T cell exhaustion. Nature Rev Immunol 2019; 19: 665-674 DOI: 10.1038/s41577-019-0221-9. (PMID: 31570879)
- 35 Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other conditions?. Nature Rev Immunol 2021; 21: 739-752